ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 203 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 0.95 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,147 | -13.0% | 199 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $4,766 | +27.3% | 199 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $3,745 | +18.2% | 199 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $3,168 | -36.6% | 199 | -29.2% | 0.00% | -33.3% |
| Q3 2022 | $5,000 | +25.0% | 281 | 0.0% | 0.00% | +50.0% |
| Q2 2022 | $4,000 | -42.9% | 281 | 0.0% | 0.00% | -50.0% |
| Q4 2021 | $7,000 | +40.0% | 281 | 0.0% | 0.00% | +33.3% |
| Q3 2021 | $5,000 | -28.6% | 281 | 0.0% | 0.00% | -25.0% |
| Q2 2021 | $7,000 | 0.0% | 281 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $7,000 | -53.3% | 281 | 0.0% | 0.00% | -60.0% |
| Q4 2020 | $15,000 | +15.4% | 281 | 0.0% | 0.01% | -23.1% |
| Q2 2020 | $13,000 | -27.8% | 281 | -42.9% | 0.01% | +8.3% |
| Q3 2019 | $18,000 | +28.6% | 492 | -5.7% | 0.01% | +33.3% |
| Q2 2019 | $14,000 | 0.0% | 522 | 0.0% | 0.01% | -18.2% |
| Q1 2019 | $14,000 | +27.3% | 522 | -5.1% | 0.01% | +120.0% |
| Q3 2018 | $11,000 | – | 550 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| March Altus Capital Management LP | 82,723 | $2,685,000 | 20.75% |
| HWG Holdings LP | 289,380 | $9,393,000 | 8.72% |
| Baker Brothers Advisors | 24,516,738 | $795,813,000 | 8.34% |
| HARVEY CAPITAL MANAGEMENT INC | 352,200 | $11,432,000 | 5.73% |
| Belmont Global Advisors, Inc. | 150,000 | $4,869,000 | 4.67% |
| Palo Alto Investors LP | 1,437,730 | $46,669,000 | 3.52% |
| Avoro Capital Advisors LLC | 329,500 | $10,696,000 | 2.38% |
| GARRISON BRADFORD & ASSOCIATES INC | 70,100 | $2,275,000 | 2.23% |
| WEATHERBIE CAPITAL, LLC | 401,642 | $13,037,000 | 1.85% |
| ACUTA CAPITAL PARTNERS, LLC | 85,999 | $2,792,000 | 1.34% |